甲癣治疗市场：按治疗类型、类型、地区划分——规模、份额、展望、机会分析，2022-2028 年

甲癣是一种真菌感染，会影响脚趾甲和手指甲，并且会影响指甲的任何部分。 药物治疗成功率高，是治疗的首选。 新一代口服抗真菌药物（伊曲康唑和特比□芬）已经取代了治疗甲癣的常规疗法。

市场动态

糖尿病患者患甲癣的风险或患病率增加，老年人口不断增加，对安全有效治疗的需求增加，越来越重视开发新的甲癣治疗方法，人们对甲癣的潜在威胁和可用治疗方法的认识不断提高预计在预测期内推动全球甲癣治疗市场增长的关键因素。

例如，2021年4月，Alembic Pharmaceuticals Limited（Alembic）宣布其合资企业Aleor Dermaceuticals Limited（Aleor）已就艾氟康唑外用溶液提交非正式新药申请（ANDA），用于治疗脚趾甲癣. 它已获得美国食品和药物管理局 (FDA) 的临时批准。

2020年10月，萌蒂推出了最新的“BETADINE”系列抗感染药物。 这种 BETADINE EMTRIX 真菌指甲溶液可有效治疗甲癣并定期使用可改善指甲外观。

这项研究的主要特点

• 本报告对全球甲癣治疗市场进行了深入分析，显示了以 2021 年为基准年的预测期（2022-2028 年）的市场规模（百万美元）和復合年增长率 (CAGR) .%）。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
• 全球甲癣治疗市场主要参与者的概况基于以下参数，包括公司亮点、产品组合、主要亮点、财务业绩和战略。
• 本研究涵盖的主要公司包括 Lumenis Ltd.、Cipla Ltd.、Bayer AG、Johnson & Johnson、Moberg Pharma AB、Pfizer Inc.、Novartis、Galderma SA、Dr. Reddys Laboratories Ltd.、Medimetriks Pharmaceuticals Inc. 和 Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）等。
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 《全球甲癣治疗市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球甲癣治疗市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按治疗类型分类
  • 市场概况：按类型分类
  • 市场概况：按地区
• 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 全球甲癣患病率上升
  • 替代治疗方案的可用性
  • 对安全有效的甲癣治疗的需求不断增加
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/批准
• 害虫分析
• 对 PORTER 的分析
• 合併/收购场景

第 4 章全球甲癣治疗市场-冠状病毒 (COVID-19) 大流行的影响

• COVID-19 的流行病学
• 供应方和需求方分析
• 经济影响

第 5 章全球甲癣治疗市场，按治疗类型，2017-2028

• 药物治疗
• 激光治疗
• 光动力疗法

第 6 章全球甲癣治疗市场，按类型，2017-2028

• 2022 年和 2028 年市场份额分析 (%)
• Y-O-Y 增长分析，2017-2028 年
• 细分趋势
• 远端甲下甲癣的治疗
  • 2017-2028 年市场规模、预测、同比增长率
• 白色浅表甲剥离
  • 2017-2028 年市场规模和预测，同比增长率
• 甲下近端甲癣
  • 市场规模和预测，同比增长率，2017-2028 年，
• 其他类型
  • 市场规模和预测，同比增长率，2017-2028 年，

第 7 章 2017-2028 年按地区分列的全球甲癣治疗市场

• 2022 年和 2028 年市场份额分析 (%)
• 2017-2028 年同比增长分析
• 细分趋势
• 北美
  • 2017-2028 年按产品类型划分的市场规模和预测，同比增长率
  • 市场规模和最终用户预测，同比增长率，2017-2028 年
• 欧洲
  • 2017-2028 年按产品类型划分的市场规模和预测，同比增长率
  • 2017-2028 年市场规模和预测，同比增长率，按最终用户分类
• 亚太地区
  • 2017-2028 年按产品类型划分的市场规模和预测，同比增长率
  • 2017-2028 年市场规模和预测，同比增长率，按最终用户分类
• 拉丁美洲
  • 市场规模和按产品类型预测，同比增长率，2017-2028 年
  • 2017-2028 年按最终用户划分的市场规模/预测和同比增长率
• 中东和非洲
  • 2017-2028 年按产品类型划分的市场规模和预测，同比增长率
  • 2017-2028 年市场规模和预测，同比增长率，按最终用户分类
• 世界其他地方
  • 市场规模和按产品类型预测，同比增长率，2017-2028 年
  • 2017-2028 年市场规模和最终用户预测以及同比增长率

第八章竞争格局

• Lumenis Ltd.
• Cipla Ltd.
• Bayer AG
• Johnson & Johnson
• Moberg Pharma AB
• Pfizer Inc.
• Novartis
• Galderma SA
• Dr. Reddys Laboratories Ltd.
• Medimetriks Pharmaceuticals Inc.
• Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）

第 9 章

• 调查方法介绍
• 关于出版商

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics:

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study:

• This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Detailed Segmentation:

• Global Onychomycosis Treatment Market, By Treatment Type:
  • Drugs
  • Laser Therapy
  • Photodynamic Therapy
• Global Onychomycosis Treatment Market, By Type:
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Other Types
• Global Onychomycosis Treatment Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Lumenis Ltd.
  • Cipla Ltd.
  • Bayer AG
  • Johnson & Johnson
  • Moberg Pharma AB
  • Pfizer Inc.
  • Novartis
  • Galderma SA
  • Reddys Laboratories Ltd.
  • Medimetriks Pharmaceuticals Inc.
  • Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of onychomycosis around the world
  • Availability of alternative treatment options
  • Rise in demand for safe/effective onychomycosis treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Onychomycosis Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Onychomycosis Treatment Market, By Treatment Type, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Laser Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Photodynamic Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Onychomycosis Treatment Market By Type, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Distal Subungual Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• White Superficial Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Proximal Subungual Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Onychomycosis Treatment Market By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

• Lumenis Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Moberg Pharma AB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Galderma SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dr. Reddys Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medimetriks Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us